HPV vaccination in Africa in the COVID-19 era: a cross-sectional survey of healthcare providers' knowledge, training, and recommendation practices.
Humans
Female
Adult
Male
Cross-Sectional Studies
Uterine Cervical Neoplasms
/ prevention & control
Papillomavirus Infections
/ prevention & control
Pandemics
Vaccination
/ psychology
Health Knowledge, Attitudes, Practice
COVID-19
/ prevention & control
Health Personnel
Africa
Papillomavirus Vaccines
/ therapeutic use
HPV
HPV vaccination
HPV-related disease
cancer control
cervical cancer
healthcare providers
vaccine hesitancy
vaccine recommendation
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2024
2024
Historique:
received:
22
11
2023
accepted:
02
01
2024
medline:
2
2
2024
pubmed:
1
2
2024
entrez:
1
2
2024
Statut:
epublish
Résumé
Although the burden of cervical cancer in Africa is highest, HPV vaccination coverage remains alarmingly low in this region. Providers' knowledge and recommendation are key drivers of HPV vaccination uptake. Yet, evidence about providers' knowledge and recommendation practices about the HPV vaccine against a backdrop of emerging vaccine hesitancy fueled by the COVID-19 pandemic is lacking in Africa. A cross-sectional study was conducted in 2021-2022 among healthcare providers involved in cervical cancer prevention activities in Africa. They were invited to report prior training, the availability of the HPV vaccine in their practice, whether they recommended the HPV vaccine, and, if not, the reasons for not recommending it. Their knowledge about the HPV vaccine was assessed through self-reporting (perceived knowledge) and with three pre-tested knowledge questions (measured knowledge). Of the 153 providers from 23 African countries who responded to the survey (mean age: 38.5 years, SD: 10.1), 75 (54.0%) were female and 97 (63.4%) were based In countries with national HPV immunization programs. Overall, 57 (43.8%) reported having received prior training on HPV vaccine education/counseling, and 40 (37.4%) indicated that the HPV vaccine was available at the facility where they work. Most respondents (109, 83.2%) reported recommending the HPV vaccine in their practice. Vaccine unavailability (57.1%), lack of effective communication tools and informational material (28.6%), and need for adequate training (28.6%) were the most commonly reported reasons for not recommending the HPV vaccine. While 63 providers (52.9%) reported that their knowledge about HPV vaccination was adequate for their practice, only 9.9% responded correctly to the 3 knowledge questions. To increase HPV vaccination coverage and counter misinformation about this vaccine in Africa, adequate training of providers and culturally appropriate educational materials are needed to improve their knowledge of the HPV vaccine and to facilitate effective communication with their patients and the community.
Identifiants
pubmed: 38299075
doi: 10.3389/fpubh.2024.1343064
pmc: PMC10829043
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1343064Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
Copyright © 2024 Fokom Domgue, Dille, Kapambwe, Yu, Gnangnon, Chinula, Murenzi, Mbatani, Pande, Sidibe, Kamgno, Traore, El Fazazi, Diop, Tebeu, Diomande, Lecuru, Adewole, Plante, Basu, Dangou and Shete.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cochrane Database Syst Rev. 2020 Jan 17;1:CD011895
pubmed: 31978259
Lancet Glob Health. 2023 Jan;11(1):e28-e29
pubmed: 36521948
Vaccine. 2018 Aug 6;36(32 Pt A):4823-4829
pubmed: 29807710
JAMA Netw Open. 2022 Nov 1;5(11):e2240801
pubmed: 36346631
Front Public Health. 2022 Mar 21;10:802947
pubmed: 35387182
Hum Vaccin Immunother. 2018;14(10):2355-2357
pubmed: 29617173
Hum Vaccin Immunother. 2023 Aug 1;19(2):2219185
pubmed: 37340826
BMC Cancer. 2019 Jun 11;19(1):563
pubmed: 31185951
Health Policy Plan. 2020 Jul 1;35(6):701-717
pubmed: 32538437
Front Public Health. 2015 Nov 26;3:269
pubmed: 26636066
BMC Public Health. 2020 Feb 4;20(1):171
pubmed: 32019543
Vaccine. 2013 Dec 29;31 Suppl 5:F32-46
pubmed: 24331746
Prev Med. 2021 Mar;144:106399
pubmed: 33388322
Clin Exp Vaccine Res. 2022 May;11(2):149-154
pubmed: 35799873
Glob Health Res Policy. 2022 Jul 19;7(1):21
pubmed: 35850783
Lancet Glob Health. 2019 Jan;7(1):e20-e21
pubmed: 30514615
Vaccine. 2018 Aug 6;36(32 Pt A):4761-4767
pubmed: 29580641
BMC Public Health. 2023 May 26;23(1):974
pubmed: 37237329
Vaccine. 2020 May 19;38(24):4001-4005
pubmed: 32336599
JAMA Pediatr. 2018 May 7;172(5):e180016
pubmed: 29507952
Prev Med. 2021 Jul;148:106554
pubmed: 33857561
EClinicalMedicine. 2021 Apr 17;34:100836
pubmed: 33997733
Wkly Epidemiol Rec. 2009 Apr 10;84(15):118-31
pubmed: 19360985
Lancet Glob Health. 2023 Jul;11(7):e1096-e1104
pubmed: 37207683
Lancet. 2019 Aug 10;394(10197):497-509
pubmed: 31255301
Front Public Health. 2023 Jul 11;11:1203610
pubmed: 37497028